Fournier’s gangrene – current concepts

• Autorzy: Wroblewska M. , Kuzaka B. , Borkowski T. , Kuzaka P. , Kawecki D. , Radziszewski P.
• Języki publikacji: EN

Abstrakty

EN

Fournier’s gangrene (FG) is a rapidly progressive form of infective necrotising fasciitis of the perineal, genital, or perianal regions, leading to thrombosis of the small subcutaneous vessels and necrosis of the overlying skin. It is believed that the occurrence of the disease in women is underreported and may be unrecognised by some clinicians. Fournier’s gangrene is a life-threatening condition, constituting an urological emergency. Many patients with Fournier’s gangrene have medical or surgical conditions, which are predisposing factors to this disease or its more severe or fatal course. These comprise diabetes mellitus, hypertension, alcoholism and advanced age. Recent reports in the literature point to changes in the epidemiology of FG, comprising an increasing age of patients. Several authors reported that the mean age of FG patients is at present 53–55 years. Prognosis in FG patients is based on FGSI (Fournier’s gangrene severity index) score. Despite the progress in medical care for FG patients, the mortality rate reported in the literature remains high – most often 20–40%, but ranges from 4% to 80%. The most common isolates cultured from FG lesions are both Gram-positive and Gram-negative, as well as strictly anaerobic bacteria. Recently community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as an etiological agent of FG with severe clinical course and even fulminant sepsis. Rarely FG may have a fungal etiology, being caused by yeast-like fungi Candida spp. or by moulds. Antibiotics should be administered parenterally and in doses high enough to reach an effective concentration in the infected tissues.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2014
• Tom: 63
• Numer: 3
• Opis fizyczny: p.267-273,fig.,ref.

Twórcy

autor

Wroblewska M.

• Institute of Haematology and Transfusion Medicine, 4 Lindleya Street, 02-005 Warsaw, Poland

autor

Kuzaka B.

• Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland

autor

Borkowski T.

• Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland

autor

Kuzaka P.

• Department of Urology, Teaching Postgraduate Hospital, Czerniakowska 231, Warsaw, Poland

autor

Kawecki D.

• Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland

autor

Radziszewski P.

• Department of Urology, Teaching Postgraduate Hospital, Czerniakowska 231, Warsaw, Poland

Bibliografia

• Abubakar A.M., M.A. Bello, B.M. Tahir and J.Y. Chinda. 2009. Fournier’s gangrene in children: a report of 2 cases. J. Surg. Tech. Case Rep. 1(1): 34–36.
• Adams J.A., D.J. Culkin, J.A. Mata, J.A. Botcchini and D.D. Venable. 1990. Fournier’s gangrene in children. Urol. 35: 439–441.
• Ahmadnia H., M. Molaei, S. Yaghoobi and E. Molaei. 2009. New prognostic factors in Fournier’s gangrene: a 10-year experience. UroToday Int. J. 2(4): doi:10.3834/uij.1944-5784.2009.08.02
• Ayan F., O. Sunamak, S.M. Paksoy, S.S. Polat, A. As, N. Sakoglu, O. Cetinkale and F. Sirin. 2005. Fournier’s gangrene: a retrospective clinical study on forty-one patients. ANZ J. Surg. 75: 1055–1058.
• Baurienne H. 1764. Sur une plaie contuse qui s’est terminee par le sphacele de la scrotum. J. Med. Chir. Pharm. 20: 251–256.
• Bednarek M. and W. Drożdż. 2008. A rare case of the extensive Fournier’s gangrene developed in the course of a perianal abscess. Przegl. Lek. 65: 410–412.
• Benjelloun el B., T. Souiki, N. Yakla, A. Ousadden, K. Mazaz, A. Louchi, N. Kanjaa and K.A. Taleb. 2013. Fournier’s gangrene: our experience with 50 patients and analysis of factors affecting mortality. World J. Emerg. Surg. 8(1): 13. doi: 10.1186/1749-7922-8-13.
• Burton M.J., P. Shah and E. Swiatlo. 2008. Community-acquired methicillin-resistant Staphylococcus aureus as a cause of Fournier’s gangrene. Am. J. Med. Sci. 335(4): 327–328.
• Capelli-Schellpfeffer M. and G.S. Gerber. 1999. The use of hyperbaric oxygen in urology. J. Urol. 162(3): 647–654.
• Capitan Manjon C., A. Tejido Sanchez, A. Suarez Charneco, J.D. Piedra Lara, G. Cruceyra Betriu, V. Martinez Silva and O. Leiva Galvis. 2003. Fournier’s gangrene: a serious infectious disease. Eur. Urol. Suppl. 2(1): 18.
• Champion S.E. 2007. A case of Fournier’s gangrene: signs and symptoms. Urol. Nurs. 27: 296–299.
• Chawla S.N., C. Gallop and J.H. Mydlo. 2003. Fournier’s gangrene: an analysis of repeated surgical debridement. Eur. Urol. 43: 572–575.
• Clayton M.D., J.E. Fowler, R. Sharifi and R.K. Pearl. 1990. Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg. Gynecol. Obstet. 170: 49–55.
• Eke N. 2000. Fournier’s gangrene: a review of 1726 cases. Br. J. Surg. 87(6): 718–728.
• Eke N. and J.E. Raphael. 2011. Fournier’s gangrene. In: Vitin A. (ed.) Gangrene – current concepts and management options. InTech. http://cdn.intechopen.com/pdfs/18914/InTech-Fournier_s_gangrene.pdf
• Erol B., A. Tuncel, V. Hanci, H. Tokgoz, A. Abdulkadir, B. Akduman and E. Kargi. 2009. Fournier’s gangrene: overview of prognostic factors and definition of new prognostic parameter. Eur. Urol. Suppl. 8: 596.
• Ersay A., G. Yilmaz, Y. Akgun and Y. Celik. 2007. Factors affecting mortality of Fournier’s gangrene: review of 70 patients. ANZ J. Surg. 77: 43–48.
• European Association of Urology (EAU), National Guideline Clearinghouse (NGC). Fournier’s gangrene. In: Guidelines on urological infections. http://www.guideline.gov/content.aspx?id=34103.
• Ferreira P.C., J.C. Reis, J.M. Amarante, A.C. Silva, C.J. Pinho, I.C. Oliveira and P.N. da Silva. 2007. Fournier’s gangrene: a review of 43 reconstructive cases. Plast. Reconstr. Surg. 119(1): 175–184.
• Fournier J.A. 1883. Gangrene foudroyante de la verge. Sem. Med. 4: 589–597.
• Gołąb A., J. Sprogis, A. Kaczmarek and A. Sikorski. 2001. Fournier’s gangrene – observation of thirteen patients (in Polish). Urol. Pol. 54(4): 83–88.
• Grabe M., T.E. Bjerklund-Johansen, H. Botto, B. Wullt, M. Çek, K.G. Naber, R.S. Pickard, P. Tenke and F. Wagenlehner. 2011. Guidelines on urological infections. Arnhem, The Netherlands: European Association of Urology (EAU); Mar.: 76–78.
• Jeong H.J., S.C. Park, I.Y. Seo and J.S. Rim. 2005. Prognostic factors in Fournier gangrene. Int. J. Urol. 12: 1041–1044.
• Johnin K., M. Nakatoh, T. Kadowaki, M. Kushima, S. Koizumi and Y. Okada. 2000. Fournier’s gangrene caused by Candida species as the primary organism. Urology 56(1): 153.
• Kalorin C.M. and E.H. Tobin. 2007. Community associated methicillin resistant Staphylococcus aureus causing Fournier’s gangrene and genital infections. J. Urol. 177(3): 967–971.
• Kara E., T. Muezzinoglu, G. Temeltas, L. Dincer, Y. Kaya, A. Sakarya and T. Coskun. 2009. Evaluation of risk factors and severity of a life threatening surgical emergency: Fournier’s gangrene (a report of 15 cases). Acta Chir. Belg. 109 (2): 191–197.
• Kim I.Y. 2011. Gangrene: the prognostic factors and validation of severity index in Fournier’s gangrene. In: A. Vitin (ed.) Gangrene – current concepts and management options. InTech. http://www. intechopen.com/books/gangrene-current-concepts-and-management-options/gangrene-the-prognostic-factors-and-validation-of-severity-index-in-fournier-s-gangrene.
• Kumar S., A. Pushkarna, V. Sharma, R. Ganesamoni and R. Nada. 2011. Fournier’s gangrene with testicular infarction caused by mucormycosis. Indian J. Pathol. Microbiol. 54: 847–848.
• Kuo C.-F., W.-S. Wang, C.-M. Lee, C.-P. Liu and H.-K. Tseng. 2007. Fournier’s gangrene: ten-year experience in a medical center in northern Taiwan. J. Microbiol. Immunol. Infect. 40: 500–506.
• Kuzaka B., R. Jardanowski and P. Dobronski. 1998. Fournier’s gangrene. A case report (in Polish). Urol. Pol. 51(1): 93–100.
• Laor E., L.S. Palmer, B.M. Tolia, R.E. Reid and H.I. Winter. 1995. Outcome prediction in patients with Fournier’s gangrene. J. Urol. 154: 89–92.
• Malkowski W. and M. Malkowski. 2006. Fournier’s gangrene (in Polish). Przegl. Urol. 2(36): 73–74.
• Malkowski W. and M. Malkowski. 2006. Fournier’s gangrene. Urol. 7(2): 75–77.
• Mallikarjuna M.N., A. Vijayakumar, V.S. Patil and B.S. Shivswamy. 2012. Fournier’s gangrene: current practices. ISRN Surgery 2012(ID 942437): 1–8.
• Montoya Chinchilla R., E. Izquierdo Morejon, B. Nicolae Pietri-cica, E. Pellicer Franco, J.L. Aguayo Albasini and B. Minana Lopez. 2009. Fournier’s gangrene. Descriptive analysis of 20 cases and literature review. Actas Urol. Esp. 33(8): 873–880.
• Pais V.M., T. Santora and D.B. Rukstalis. 2013. Fournier gangrene. http://emedicine.medscape.com/article/2028899
• Palmer L.S., H.I. Winter, B.M. Tolia, R.E. Reid and E. Laor. 1995. The limited impact of involved surface area and surgical débridement on survival in Fournier’s gangrene. Br. J. Urol. 76(2): 208–212.
• Paty R. and A.D. Smith. 1992. Gangrene and Fournier’s gangrene. Urol. Clin. North Am. 19: 149–162.
• Pawłowski W., M. Wroński and I.W. Krasnodębski. 2004. Fournier’s gangrene (in Polish). Pol. Merkur. Lek. 17 (97): 85–87.
• Rutchik S. and M. Sanders. 2003. Fungal Fournier gangrene. Infect. Urol. 16: 54–56.
• Sarvestani A., M. Zamiri and M. Sabouri. 2013. Prognostic factors for Fournier’s gangrene; a 10-year experience in Southeastern Iran. Bull. Emerg. Trauma 1(3): 116–122.
• Saijo S., Y. Kuramoto, M. Yoshinari and H. Tagami. 1990. Extremely extended Fournier’s gangrene. Dermatol. 181(3): 228–232.
• Samet A., S. Chabielski, M. Stasiak, M. Bronk and J. Lasek. 2009. Usage of tigecycline as new antibiotic monotherapy option in treatment of Fournier gangrene (in Polish). Zakażenia 4/2009: 93–97.
• Silva J., J. Gomes, P. Vendeira, P. Diniz, F. Cruz and M. Reis. 2002. Fournier’s gangrene: ten year experience at a single institution. Eur. Urol. Suppl. 1: 178.
• Smith G.L., C.B. Bunker and M.D. Dinneen. 1998. Fournier’s gangrene. Br. J. Urol. 81: 347–355.
• Sohu K.M., A.A. Shah, S.H. Mirani, G.H. Rind and B. Shaikh. 2013. Etiological factors and treatment outcome of genital and perineal necrotizing fascitis (Fournier’s gangrene). Rawal Med. J. 38(2): 160–164.
• Sorensen M.D., J.N. Krieger, F.P. Rivara, J.A. Broghammer, M.B. Klein, C.D. Mack and H. Wessells. 2009. Fournier’s gangrene: population based epidemiology and outcomes. J. Urol. 181(5): 2120–2126.
• Sugihara T., H. Yasunaga, H. Horiguchi, T. Fujimura, K. Ohe, Matsuda S., Fushimi K and Y. Homma. 2012. Impact of surgical intervention timing on the case fatality rate for Fournier’s gangrene: an analysis of 379 cases. BJU Int. 110(11): E1096–1100.
• Tahmaz L., F. Erdemir, Y. Kibar, A. Cosar and O. Yalcyn. 2006. Fournier’s gangrene: report of thirty-three cases and review of the literature. Int. J. Urol. 13: 960–967.
• Thwaini A., A. Khan, A. Malik, J. Cherian, J. Barua, I. Shergill and K. Mammen. 2006. Fournier’s gangrene and its emergency management. Postgrad. Med. J. 82(970): 516–519.
• Tuncel A., O. Aydin, U. Tekdogan, V. Nalcacioglu, Y. Capar and A. Atan. 2006. Fournier’s gangrene: three years of experience with 20 patients and validity of the Fournier’s Gangrene Severity Index score. Eur. Urol. 50: 838–843.
• Ulug M., E. Gedik, S. Girgin, M. Celen and C. Ayaz. 2009. The evaluation of microbiology and Fournier’s gangrene severity index in 27 patients. Int. J. Infect. Dis. 13: e424–e430.
• Wong C.H., L.W. Khin, K.S. Heng, K.C. Tan and C.O. Low. 2004. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit. Care Med. 32(7): 1535–1541.
• Yeniyol C.O., T. Suelozgen, M. Arslan and A.R. Ayder. 2004. Fournier’s gangrene: experience with 25 patients and use of Fournier’s gangrene severity index score. Urol. 64: 218–222.